| Project/Area Number |
13470284
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
TANAKA Minoru (2002-2004) The University of Tokyo, Faculty of Medicine, Assistant, 医学部附属病院, 助手 (50332581)
植木 敬介 (2001) 東京大学, 医学部・附属病院, 助手 (20302705)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ABURATANI Hiroyuki The University of Tokyo, Research Center for Advanced Science and Technology, Professor, 先端科学技術研究センター, 教授 (10202657)
UEKI Keisuke Dokkyo University School of Medicine, Faculty of Medicine, Assistant Professor, 医学部, 助教授 (20302705)
ASAI Akio Saitama Medical School, Saitama Medical Center, Assistant Professor, 総合医療センター, 助教授 (50231858)
田中 実 東京大学, 医学部・附属病院, 助手 (50332581)
|
|---|
| Project Period (FY) |
2001 – 2004
|
| Project Status |
Completed (Fiscal Year 2004)
|
| Budget Amount *help |
¥13,700,000 (Direct Cost: ¥13,700,000)
Fiscal Year 2004: ¥1,400,000 (Direct Cost: ¥1,400,000)
Fiscal Year 2003: ¥2,100,000 (Direct Cost: ¥2,100,000)
Fiscal Year 2002: ¥4,200,000 (Direct Cost: ¥4,200,000)
Fiscal Year 2001: ¥6,000,000 (Direct Cost: ¥6,000,000)
|
|---|
| Keywords | oligodendroglioma / 1p, 19q LOH / microarray / astrocytoma / glioblastoma / 遺伝子診断 / 化学療法 / 遺伝子発現解析 |
|---|
| Research Abstract |
This research investigated deficit of a chromosome (1p, 19q, 10q, CDKN2N), and variation of a gene TP53, and amplification of EGFR or CDK4 in many clinical samples of a tumor bank. Many of tumors accompanied by 1p deficit are oligodendroglioma, and it is in about 60% of the oligodendroglioma. It was simultaneously accompanied by the deficit of 19q. In the oligodendroglioma without the deficit of chromosome 1p, many gene variation of p53 was accepted.
Next, the drug susceptibility in chemotherapy related gene of the oligodendroglioma. A profile analysis of chromosome 1p was performed by a microarray (DNA chip) for the purpose of the antioncogene identification assumed to be on chromosome 1p. Consequently, chemotherapy susceptibility is high among oligodendroglioma accompanied by the deficit of single-sided allele of 1p. For the first time 209 genes changing intentionally on chromosome 1p, and the 123 genes considered an antioncogene, were identified.
Furthermore, for astrocytoma or glioblastoma gene expression profile analysis was performed by Gene chip, and comparison analysis with the oligodendroglioma was enforced. It became clear that the gene amplified in oligodendroglioma with high chemotherapy susceptibility was the gene cluster to a neuron. Moreover, some genes discovered characteristic of astrocytoma or the glioblastoma were also identified. Although, as for two examples of astrocytoma (WHO Grade II), the discovery profile resembled glioblastoma (WHO Grade IV), the prognosis of these cases was actually poor and, also clinically, showed progress like glioblastoma.
Thus, a gene expression profile can serve as a tool which presumes the prognosis of each case.
|
